CWIAX
Price
$82.59
Change
+$0.54 (+0.66%)
Updated
Jun 2 closing price
Net Assets
151.89B
VESGX
Price
$52.31
Change
+$0.32 (+0.62%)
Updated
Jun 2 closing price
Net Assets
1.48B
Interact to see
Advertisement

CWIAX vs VESGX

Header iconCWIAX vs VESGX Comparison
Open Charts CWIAX vs VESGXBanner chart's image
CWIAX vs VESGX Comparison Chart in %
View a ticker or compare two or three
VS
CWIAX vs. VESGX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CWIAX is a Buy and VESGX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CWIAX has more cash in the bank: 152B vs. VESGX (1.48B). VESGX pays higher dividends than CWIAX: VESGX (1.53) vs CWIAX (1.33). CWIAX was incepted earlier than VESGX: CWIAX (24 years) vs VESGX (7 years). CWIAX (0.75) is less costly to investors than VESGX (0.48). VESGX is a more actively managed with annual turnover of: 47.00 vs. CWIAX (44.00). CWIAX has a lower initial minimum investment than VESGX: CWIAX (250) vs VESGX (50000). CWIAX annual gain was more profitable for investors over the last year : 22.44 vs. VESGX (10.75). VESGX (38.25) and CWIAX (38.19) have equivalent 5 years return.
CWIAXVESGXCWIAX / VESGX
Total Expense Ratio0.750.48156%
Annual Report Gross Expense Ratio0.750.48156%
Fund Existence24 years7 years-
Gain YTD15.6527.841200%
Front Load4%N/A-
Min. Initial Investment250500001%
Min. Initial Investment IRAN/AN/A-
Net Assets152B1.48B10,256%
Annual Yield % from dividends1.331.5387%
Returns for 1 year22.4410.75209%
Returns for 3 years54.6538.25143%
Returns for 5 years38.1938.25100%
Returns for 10 years122.63N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSHAX12.600.20
+1.61%
NYLI Cushing® MLP Premier Class A
JCPRX25.76N/A
N/A
JPMorgan US Large Cap Core Plus R5
OIEIX26.19N/A
N/A
JPMorgan Equity Income A
RYBOX65.18N/A
N/A
Rydex Biotechnology A
PSKCX23.33N/A
N/A
Virtus KAR Mid-Cap Growth C